Text this: 1118P Time to quality of life (QoL) deterioration in patients (pts) with mismatch repair proficient/microsatellite stable (MMRp/MSS) primary advanced or recurrent endometrial cancer (pA/rEC) and by population subgroups in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial